NCT01741103

Sitagliptin in Type I Diabetic Patients

Effect of Sitagliptin on Glycemic Control, Post-prandial Glucagon, and Inflammation in Type 1 Diabetics

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University at Buffalo · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the effect of sitagliptin on overall blood glucose concentrations in Type I Diabetic subjects. The study also aims to evaluate post meal glucagon concentrations in Type I Diabetic subjects (a possible mechanism of reduced blood glucose concentrations) and indices of oxidation stress in the plasma of these subjects.

Detailed description

The hypothesis is that Sitagliptin will improve overall blood glucose, fasting blood glucose, and glycemic excursions in patients with Type I Diabetes. In addition, sitagliptin will likely suppress indices of oxidative stress in patients. The study will investigate proposed mechanisms of improved glucose concentrations, including enhanced effect of endogenous GLP-1 and suppression of glucagon.

Conditions

• Diabetes Type I

Interventions

Type	Name	Description
DRUG	sitagliptin	sitagliptin 100mg by mouth once a day for 12 weeks
DRUG	Placebo	Take one by mouth daily for 12 weeks

Timeline

• Start date: 2011-06-01
• Primary completion: 2013-09-01
• Completion: 2013-09-01
• First posted: 2012-12-04
• Last updated: 2022-03-24

Locations

1 site across 1 country: United States